FDA Approves Ivosidenib for Myelodysplastic Syndromes

On October 24, the US Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation, as detected by an FDA-approved test.

For more information read the FDA announcement.

Posted 10/27/2023